All Blogs
Mar 25, 2026
Molecular Diagnostics: Bridging the Gap Between Diagnosis and Treatment
Molecular diagnostics is a rapidly advancing field within laboratory medicine that applies molecular biology techniques to detect and quantify specific DNA or RNA sequences. By enabling earlier detection, greater diagnostic accuracy, and more informed clinical decision-making, these technologies have become indispe...
Read More...
Mar 24, 2026
Sanofi’s Venglustat Gains US Breakthrough Therapy Nod, Boosting Hope for Type 3 Gaucher Disease; Rhythm Pharmaceuticals Expands IMCIVREE Label with FDA Approval in Hypothalamic Obesity; FDA Approves LYNAVOY for Cholestatic Pruritus in PBC Patients; FDA Greenlights J&J/Protagonist’s ICOTYDE, Redefining First-Line Systemic Therapy for Plaque Psoriasis; Novartis Strengthens its Breast Cancer Portfolio Through Acquisition of a Pan-mutant PI3Kα Inhibitor
Sanofi Wins US Breakthrough Therapy Tag for Venglustat in Type 3 Gaucher Disease The US Food and Drug Administration (FDA) has awarded Breakthrough Therapy designation to venglustat, an investigational oral glucosylceramide synthase inhibitor (GCSi), for treating neurological symptoms associated with type 3 Gauc...
Read More...
Mar 23, 2026
J&J and Protagonist’s ICOTYDE Ushers in First-in-Class Oral IL-23 Therapy
Summary Johnson & Johnson and Protagonist Therapeutics received U.S. FDA approval for ICOTYDE (icotrokinra), the first targeted oral IL-23 receptor peptide therapy for moderate-to-severe plaque psoriasis in adults and adolescents (12+ years, ≥40 kg). Once-daily 200 mg oral tablet blocks IL-23 signaling w...
Read More...
Mar 20, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Summary Radioligand therapy is quickly establishing itself as a transformative force in oncology, with demand accelerating so rapidly that manufacturers are under pressure to scale up production. Among the leaders, Novartis is advancing its late-stage candidate 225Ac-PSMA-617, while a growing competitive lan...
Read More...
Mar 19, 2026
MiniMed Secures FDA Clearance for MiniMed Flex; Spinal Elements Expands Portfolio with FDA-Cleared Ventana® Platform and Initial ALIF Launch; Mindray North America Strengthens Respiratory Care Offering Through Ventilator Market Entry; Micro-Tech Endoscopy Enters Definitive Deal to Acquire Key GI Product Lines from CONMED; Composite Manufacturing Inc. Unveils Study Showing NekSpine® Exoskeleton Eases Neck and Back Load During Simulated Surgeries; SkinVision Partners on Landmark Trial to Expand Dermatology Care Access in the U.S.
MiniMed Announced the FDA Clearance of MiniMed Flex™, the Company's Smallest Insulin Pump Featuring its First Smartphone-Controlled Design On 18 March 2026, MiniMed announced that it had received clearance from the U.S. Food and Drug Administration (FDA) for its MiniMed Flex™, a next-generation, discreet i...
Read More...
Mar 18, 2026
Defibrillators at the Heart of Cardiac Care: Challenges, Innovations, and the Road Ahead
Defibrillators are critical medical devices designed to correct life-threatening cardiac arrhythmias, particularly ventricular fibrillation and ventricular tachycardia, which can rapidly lead to sudden cardiac arrest (SCA). By delivering a controlled electrical shock to the heart, defibrillators aim to restore a no...
Read More...
Mar 17, 2026
Sana Biotechnology Reveals Long-Term Positive Data from Type 1 Diabetes Islet Cell Transplant Trial; Bayer’s Finerenone Demonstrates Efficacy in Phase III FIND-CKD Study in Non-Diabetic CKD Population; Immutep Halts Phase III NSCLC Trial; REGENXBIO’s RGX-202 Demonstrates Promising Interim Results in Phase I/II AFFINITY DUCHENNE Trial; Ultragenyx’s DTX301 Gene Therapy Delivers Positive 36-Week Phase 3 Data
Sana Biotechnology Reports Sustained Positive 14-Month Results from Type 1 Diabetes Islet Cell Transplant Study Without Immunosuppression Sana Biotechnology reported continued positive clinical results from its cell therapy programs, reinforcing its broader strategy of developing engineered cells as medicines. T...
Read More...
Mar 16, 2026
The Underactive Bladder Syndrome Treatment Landscape: Few Contenders, High Unmet Need
Summary The current treatment landscape for underactive bladder largely depends on pharmacological management and catheterization. Despite the significant unmet need, the clinical development pipeline for UAB remains relatively sparse. Notable candidates include TAC-302, being developed by Taiho Pharmace...
Read More...
Mar 13, 2026
SOTYKTU Expands Its Reach as Bristol Myers Squibb Lands Key Approval in Psoriatic Arthritis
Summary Bristol Myers Squibb’s SOTYKTU has received FDA approval for adults with active psoriatic arthritis, becoming the first and only TYK2 inhibitor authorized for this indication. The drug extends its reach beyond its 2022 approval for moderate-to-severe plaque psoriasis, reinforcing BMS’s bid to b...
Read More...
Mar 12, 2026
QT Imaging Secures FDA Clearance for Enhanced Breast Acoustic CT Scanner Configuration; LifeVac Secures FDA Authorization as the First and Only Anti-Choking Device; Smith+Nephew Introduces Next-Generation ALLEVYN COMPLETE CARE Foam Dressing for Enhanced Wound Management; Olympus Corporation Debuts Next-Gen Surgical Visualization Platform in the U.S.; IceCure Medical Receives FDA Approval for Post-Marketing ‘CHOICE’ Study of ProSense Cryoablation System; Envoy Medical Concludes Enrollment for Landmark Trial of Fully Implanted Cochlear Implant
QT Imaging Received FDA Clearance for its Breast Acoustic CT Scanner Enhanced Configuration to Improve Posterior Breast Imaging Coverage On 10 March 2026, QT Imaging Holdings, Inc., a medical device company focused on advancing breast health management through innovative radiation-free imaging technology, ...
Read More...